Eyepoint Inc (EYPT) - News Archive

In a significant boost for the field of ophthalmology, EyePoint Pharmaceuticals has announced a positive recommendation from the Independent Data Safety Monitoring Committee (DSMC) regarding its pivotal Phase 3 trials f...

EyePoint Pharmaceuticals Expands Employee Incentives and Strengthens Financial Position Amid Market ActivityWATERTOWN, Mass. March 17, 2025 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company devoted to the develop...

EyePoint Pharmaceuticals Boosts Talent with Inducement Grants: What It Means for InvestorsIn a significant move that reflects its continued commitment to fostering growth and attracting talent, EyePoint Pharmaceuticals,...

EyePoint Pharmaceuticals: Strategic Growth and Promising Developments in OphthalmologyIn an era where the pharmaceutical industry faces rigorous competition and rapid advancements, EyePoint Pharmaceuticals, Inc. (NASDAQ...

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering: A Strategic Leap Towards Growth and InnovationWatertown, Mass. October 29, 2024 EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pivotal player in t...

EyePoint Pharmaceuticals Expands Growth Horizon with Major Public Offering: Insights and ImplicationsOn October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company focused on innovative therape...

EyePoint Pharmaceuticals Grants Inducement Awards to New Employees Outside of Long-Term Incentive PlanEyePoint Pharmaceuticals, a leading developer and marketer of therapeutics for serious retinal diseases, has recently...

EyePoint Pharmaceuticals, a leading pharmaceutical company dedicated to enhancing the lives of patients with serious retinal diseases, has announced the hosting of an exclusive Research and Development (R&D) Day. The ev...

By EyePoint Pharmaceuticals, a leading biopharmaceutical company specializing in the development and commercialization of therapies for serious retinal diseases, recently announced the grant of non-statutory stock optio...

In the ongoing quest to identify effective treatments for non-proliferative diabetic retinopathy (NPDR), EyePoint Pharmaceuticals recently announced significant findings from the Phase 2 PAVIA trial of their experimenta...

EyePoint Pharmaceuticals, a leading company dedicated to enhancing the lives of patients with serious retinal diseases, has recently announced the granting of non-statutory stock options to new employees. These induceme...

EyePoint Pharmaceuticals, a leading company dedicated to enhancing the lives of patients with retinal diseases, has recently made an exciting announcement regarding inducement grants. By granting non-statutory stock opt...

Sophisticated EyePoint Pharmaceuticals Unveils Promising Subgroup Analysis Results for EYP-1901 in Phase 2 DAVIO 2 Clinical TrialEyePoint Pharmaceuticals, a leading developer and marketer of therapeutic solutions for re...

EyePoint Pharmaceuticals Grants Inducement Stock Options and Successfully Completes Public Offerings to Support Growth in the Treatment of Retinal DiseasesWATERTOWN, Mass., Jan. 16, 2024 - EyePoint Pharmaceuticals, Inc....

Innovative Therapeutic Approaches: EyePoint Pharmaceuticals Launches Phase 2 VERONA Clinical Trial for DME Treatment with EYP-1901In the domain of ophthalmic therapeutics, EyePoint Pharmaceuticals, Inc., a prominent pla...

EyePoint Pharmaceuticals, a leading company focused on developing and commercializing therapeutics for serious retinal diseases, has announced the successful closure of its underwritten public offering. The offering con...

EyePoint Pharmaceuticals Sets Pricing for Public Offering, Expecting $200 Million in Gross ProceedsEyePoint Pharmaceuticals, a biopharmaceutical company dedicated to improving the lives of patients with serious retinal...

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock and Impressive Revenue Growth in Q3 2023WATERTOWN, Mass., Dec. 04, 2023 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a leading biopharmaceu...